Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s Financial Overview
Halozyme Therapeutics, Inc. (NASDAQ) surged 1.65% yesterday to close its trading session at $16.65. The company has 1 year Price Target of $21. Halozyme Therapeutics, Inc. has 52-Week high of $21.48 and 52-Week Low of $13.24. The stock touched its 52-Week High on 21.48 and 52-Week Low on 13.24. The stock traded with the volume of 506126 shares yesterday. The firm shows the market capitalization of $2.39 Billion.
Halozyme Therapeutics, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.19/share against the analyst consensus estimate of $-0.23/share. The difference between the actual and expected EPS is $0.04 a share with a surprise factor of 17.4%.
The firm is trading with SMA20 of 2.86 Percent, SMA50 of 7.34 Percent and SMA200 of -2.56 percent. Halozyme Therapeutics, Inc. has P/S value of 8.51 while its P/B value stands at 9.97. Similarly, the company has Return on Assets of 9.4 percent, Return on Equity of 18.9 percent and Return on Investment of 20.1 Percent. The company shows Gross Margin and Operating Margin of 95.7 percent and 20.2 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 11 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 20.00, with a high estimate of 33.00 and a low estimate of 9.00. The median estimate represents a +20.12% increase from the last price of 16.65.
Halozyme Therapeutics, Inc. is expected* to report earnings on 02/21/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.02. The reported EPS for the same quarter last year was $0.85.
LPL Financial Holdings Inc. (NASDAQ:LPLA)
LPL Financial Holdings Inc. is engaged in providing an integrated platform of brokerage and investment advisory services to independent financial advisors and financial advisors at financial institutions in the United States. Its brokerage offerings include variable and fixed annuities, mutual funds, general securities, alternative investments, retirement plans, fixed income, and insurance offerings. LPL Financial Holdings Inc., formerly known as LPL Investment Holdings Inc., is based in Boston, Massachusetts.
LPL Financial Holdings Inc. (NASDAQ:LPLA)’s Financial Outlook
The 8 analysts offering 12-month price forecasts for LPL Financial Holdings Inc have a median target of 82.00, with a high estimate of 100.00 and a low estimate of 66.00. The median estimate represents a +5.47% increase from the last price of 77.75.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, LPL Financial Holdings Inc. has a Consensus Recommendation of 2.29. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -0.21% and closed its last trading session at $77.75. The company has the market capitalization of $6.72 Billion. The stock has 52-week high of $79.34 and 52-Week low of $52.03. The firm touched its 52-Week high on 78.29 and 52-Week low on 52.03. The company has volume of 758096 shares. The company has a total of 86.47 Million shares outstanding.
LPL Financial Holdings Inc. (NASDAQ) in the last quarter reported its actual EPS of $1.49/share where the analyst estimated EPS was $1.37/share. The difference between the actual and Estimated EPS is $0.12. This shows a surprise factor of 8.8 percent.
The company has YTD performance of 27.29 percent. Beta for LPL Financial Holdings Inc. stands at 1.6 while its ATR (average true range) is 1.98. The company has Weekly Volatility of 1.87%% and Monthly Volatility of 2.76%%.
LPL Financial Holdings Inc. has distance from 20-day Simple Moving Average (SMA20) of 8.22%, Distance from 50-Day Simple Moving Average of 18.77 percent and Distance from 200-Day Simple Moving Average of 18.73%.
The Company currently has ROA (Return on Assets) of 6.3 percent, Return on Equity (ROE) of 33.8 Percent and Return on Investment (ROI) of 9.3% with Gross margin of 98.8 percent and Operating & Profit margin of 11.1% and 6.4% respectively.